EQUITY RESEARCH – RESULTS FLASH



รายงานผลประกอบการ 4Q23

PR9 รายงานรายได้ EBITDA margin และกำไรปกติทำสถิติสูงสุดใหม่ที่ 188 ลบ. ใน 4Q23 สูงกว่าที่เราคาด

Highlights

- PR9 รายงานกำไรปกติ 4Q23 ทำสถิติสูงสุดใหม่ที่ 188 ลบ. (+36% y-y, +34% q-q) สูง กว่าที่ตลาดและเราคาด 10% จาก EBITDA margin ที่สูงเกินคาด
- รายได้โต 6% y-y โดยมีรายได้จากผู้ป่วยชาวไทยโต 6% y-y ในขณะที่รายได้จากผู้ป่วย ต่างชาติเพิ่ม 9% y-y นำโดยรายได้จากผู้ป่วยชาวพม่า จีนและเขมรที่สูงขึ้น
- รายได้จากผู้ป่วยชาวไทยและต่างชาติทำสถิติสูงสุดใหม่และสูงกว่าระดับก่อนโควิด 57% และ 50% ตามลำดับ
- สัดส่วนรายได้จากผู้ป่วยชาวไทยคิดเป็น 86% ในไตรมาสนี้ในขณะที่รายได้จากผู้ป่วย ต่างชาติคิดเป็น 14%
- ค่าใช้จ่ายการขายและบริหารลดลง 4% y-y จากฐานที่สูงใน 4Q22 จากค่าใช้จ่ายโบนัสที่ จ่ายให้แก่พนักงาน ตันทุนขายเพิ่ม 4% y-y ตามรายได้ที่สูงขึ้นซึ่งทำให้ EBITDA margin กระโดดเพิ่มเป็น 26% ใน 4Q23 (เทียบกับ 22% ใน 4Q22) นับว่าเป็นสถิติสูงสุดใหม่ (ไม่ รวมช่วงที่โควิดระบาด)
- PR9 ประกาศจ่ายเงินปันผล 0.3 บาท/หุ้นคิดเป็นผลตอบแทนในรูปเงินปันผลที่ 2%

Outlook and recommendation

- เราคาดว่า Momentum การเติบโตจะเกิดต่อเนื่องใน 1Q24 ปริมาณผู้ป่วยในยังอยู่ใน เกณฑ์ดีในเดือน ม.ค. และ ก.พ. นอกจากนี้ PR9 ยังได้เริ่มให้บริการผู้ป่วยชาวตะวันออก กลาง เพราะฉะนั้นเราจึงคาดว่ากำไรจะโตดี y-y ใน 1Q24
- PR9 มีการซื้อขายในระดับการประเมินมูลค่าที่ต่ำเพียง 23x ของค่า 2024E P/E (เทียบ กับค่าเฉลี่ยของกลุ่มฯ ที่ 26x) และเป็นหนึ่งในหุ้นเด่นของเราในกลุ่ม Mid-small caps จากแนวโน้มที่ดีของบริษัทฯ



BUY

UNCHANGED

TARGET PRICE	THB22.00
CLOSE	THB17.80
UP/DOWNSIDE	+23.6%
PRIOR TP	THB22.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	+10.7%

KEY STOCK DATA

PR9 TB

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	4,202	4,549	4,826	5,120
Net profit	558	603	656	721
EPS (THB)	0.71	0.77	0.83	0.92
vs Consensus (%)	-	15.6	11.6	11.5
EBITDA	958	1,057	1,138	1,237
Recurring net profit	558	603	656	721
Core EPS (THB)	0.71	0.77	0.83	0.92
Chg. In EPS est. (%)	nm	0.0	0.0	nm
EPS growth (%)	(1.7)	8.2	8.7	9.9
Core P/E (x)	25.1	23.2	21.3	19.4
Dividend yield (%)	1.7	2.2	2.3	2.6
EV/EBITDA (x)	12.6	11.1	9.9	8.8
Price/book (x)	2.8	2.6	2.4	2.3
Net debt/Equity (%)	(37.3)	(42.3)	(46.5)	(50.5)
ROE (%)	11.4	11.5	11.7	12.0



Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

บทวิเคราะห์ฉบับนี้แปลมาจากต้นฉบับภาษาอังกฤษ ที่ออกรายงานเมื่อวันที่ 20 กุมภาพันธ์ 2024

Exhibit 1: PR9 - 4Q23 results summary

FY ending Dec	4Q22	1Q23	2Q23	3Q23	4Q23	Cha	nae	2023	2024E	Change
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)
Sales	1,103	957	1,005	1,066	1,175	10	6	4,202	4,549	رہ رور ا 8
COGS (incl depreciation)	(730)	(657)	(688)	(714)	(761)	6	4	(2,820)	(3,048)	8
Gross profit	373	300	(000) 316	351	414	18	11	1,382	1,501	9
SG&A	(218)	(182)	(185)	(198)	(209)	6	(4)	(774)	(818)	6
Operating profit	155	118	132	154	(200) 205	33	(" / 32	(// -) 608	683	12
Net other income	133	16	17	19	203	35 45	52 67	81	71	(12)
Interest expenses	(0)	(0)	(0)	(0)	(0)	40	07	(1)	0	(12) n/a
Pretax profit	(0) 172	(0) 134	(0) 149	(0) 173	233	35	36	(1) 689	754	10a 10
Income Tax	(33)					35 36	30 35	(131)	(151)	15
Core profit	(33) 139	(25) 109	(28) 121	(33) 140	(45) 188	30 34	35 36	(131) 558	(151) 603	13 8
•	139	109	121	140	100	34	30	000	603	o
Extraordinaries, GW & FX	400	400	404	4.40	400		20		600	
Reported net profit	139	109	121	140	188	34	36	558	603	8
Outstanding shares (m)	786	786	786	786	786	0	0	786	786	0
Pre-ex EPS (THB)	0.18	0.14	0.15	0.18	0.24	34	36	0.71	0.77	8
EPS (THB)	0.18	0.14	0.15	0.18	0.24	34	36	0.71	0.77	8
COGS excl. depreciation	(656)	(584)	(614)	(638)	(686)	7	4	(2,521)	(2,725)	8
Depreciation	(74)	(73)	(75)	(76)	(75)	(1)	1	(299)	(323)	8
EBITDA	246	207	224	249	308	24	25	988	1,077	g
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	34	31	31	33	35	2	1	33	33	C
SG&A/Revenue	20	19	18	19	18	(1)	(2)	18	18	(0)
EBITDA margin	22	21	22	23	26	3	4	23	23	C
Net profit margin	13	11	12	13	16	3	3	13	13	(0)
Operating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	20	6	5	4	3					
OPD volume growth y-y	13	8	4	5	-					
OPD revenue per head growth y-y	6	(2)	1	(0)	-					
IPD revenue growth y-y	15	(11)	1	(5)	12					
IPD volume growth y-y	5	(35)	(10)	(11)	-					
IPD revenue per head growth y-y	10	38	13	6	-					
Thai patient revenue growth y-y	11	(5)	4	1	6					
Inter patient revenue growth y-y	96	29	1	(5)	9					

Sources: PR9; FSSIA estimates

Exhibit 2: EBITDA margin





Exhibit 3: Core profit



Sources: PR9; FSSIA estimates

Sources: PR9; FSSIA estimates

Financial Statements

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	4,107	4,202	4,549	4,826	5,120
Cost of goods sold	(2,724)	(2,820)	(3,048)	(3,224)	(3,406)
Gross profit	1,384	1,382	1,501	1,602	1,714
Other operating income	43	51	51	52	53
Operating costs	(735)	(774)	(818)	(859)	(896)
Operating EBITDA	991	958	1,057	1,138	1,237
Depreciation	(299)	(299)	(323)	(343)	(365)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	692	659	734	795	872
Net financing costs	8	30	20	25	29
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	700	689	754	820	901
Tax	(132)	(131)	(151)	(164)	(180)
Profit after tax	568	558	603	656	721
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	568	558	603	656	721
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	568	558	603	656	721
Per share (THB)					
Recurring EPS *	0.72	0.71	0.77	0.83	0.92
Reported EPS	0.72	0.71	0.77	0.83	0.92
DPS	0.29	0.30	0.38	0.42	0.46
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth					
Revenue (%)	37.5	2.3	8.3	6.1	6.1
Operating EBITDA (%)	67.9	(3.4)	10.3	7.7	8.6
Operating EBIT (%)	133.3	(4.7)	11.4	8.3	9.7
Recurring EPS (%)	127.8	(1.7)	8.2	8.7	9.9
Reported EPS (%)	127.8	(1.7)	8.2	8.7	9.9
Operating performance					
Gross margin inc. depreciation (%)	33.7	32.9	33.0	33.2	33.5
Gross margin exc. depreciation (%)	41.0	40.0	40.1	40.3	40.6
Operating EBITDA margin (%)	24.1	22.8	23.2	23.6	24.2
Operating EBIT margin (%)	16.8	15.7	16.1	16.5	17.0
Net margin (%)	13.8	13.3	13.3	13.6	14.1
Effective tax rate (%)	18.9	19.0	20.0	20.0	20.0
Dividend payout on recurring profit (%)	40.2	42.3	50.0	50.0	50.0
Interest cover (X)	(84.0)	(22.3)	(36.8)	(32.1)	(30.1)
Inventory days	8.1	7.2	6.7	6.8	6.8
Debtor days	20.2	23.1	23.3	21.9	20.7
Creditor days	82.5	73.9	72.7	73.5	73.5
Operating ROIC (%)	18.1	17.6	19.3	21.2	23.5
ROIC (%)	17.4	16.1	17.5	19.2	21.2
ROE (%)	12.6	11.4	11.5	11.7	12.0
ROA (%)	10.5	9.3	9.6	9.7	10.1
* Pre-exceptional, pre-goodwill and fully diluted		0.0	0.0		
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
OPD patient revenue	2,383	2,491	2,621	2,781	2,950

Sources: Praram 9 Hospital; FSSIA estimates

Financial Statements

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
ecurring net profit	568	558	603	656	721
epreciation	299	299	323	343	365
ssociates & minorities	-	-	-	-	
ther non-cash items	10	10	0	0	(
change in working capital	(5)	(23)	46	35	37
Cash flow from operations	871	844	972	1,034	1,122
Capex - maintenance	(140)	(326)	(323)	(343)	(364
Capex - new investment	-	-	-	-	
let acquisitions & disposals	(150)	(100)	0	0	(
Other investments (net)	-	-	-	-	(0.0.1
Cash flow from investing	(290)	(426)	(323)	(343)	(364
Dividends paid	(110)	(234)	(236)	(302)	(328
Equity finance	0	0	0	0	(
Debt finance	2 0	1 0	0 0	0 0	(
Dther financing cash flows Cash flow from financing	(108)	(233)		(302)	
-	(100)	(233)	(236)	(302)	(328
Non-recurring cash flows Dther adjustments	-	- 0	- 0	- 0	(
Net other adjustments	0	0	0	0	(
Aovement in cash	473	184	413	390	430
Free cash flow to firm (FCFF)	581.44	418.17	648.69	691.26	757.76
ree cash flow to equity (FCFE)	581.44	418.73	648.69	691.26	757.76
	502.47	-10.75	5-0.03	551.20	131.10
er share (THB)					
CFF per share	0.74	0.53	0.82	0.88	0.96
CFE per share	0.74	0.53	0.82	0.88	0.96
Recurring cash flow per share	1.11	1.10	1.18	1.27	1.38
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross) ess: Accumulated depreciation	5,638 (2,322)	5,898 (2,556)	6,222 (2,878)	6,565 (3,222)	6,929 (3,586)
	(2,322) 3,315	(2,556) 3,343	(2,878) 3,343	(3,222) 3,343	(3,566) 3,34 3
angible fixed assets (net) ntangible fixed assets (net)	3,315	3,343 0	3,343 0	3,343 0	3,343
.ong-term financial assets	U	U	U	U	,
nvest. in associates & subsidiaries	154	254	254	254	254
Cash & equivalents	1,717	1,901	2,314	2,704	3,134
VC receivable	243	290	290	290	290
nventories	51	48	52	55	
Other current assets	12	12	13	14	14
Current assets	2,023	2,251	2,669	3,063	3,496
Dther assets	65	62	62	62	62
Fotal assets	5,558	5,910	6,328	6,722	7,155
Common equity	4,735	5,080	5,447	5,801	6,194
Ainorities etc.	0	0	0	0	0,10
Total shareholders' equity	4,735	5,080	5,447	5,801	6,194
.ong term debt	8	9	9	9	, g
Other long-term liabilities	209	195	195	195	195
ong-term liabilities	217	204	204	204	204
VC payable	499	522	564	596	629
Short term debt	0	0	0	0	(
Other current liabilities	106	105	113	120	127
Current liabilities	606	626	677	716	757
otal liabilities and shareholders' equity	5,558	5,910	6,328	6,722	7,155
let working capital	(299)	(276)	(322)	(357)	(394
nvested capital	3,235	3,382	3,337	3,302	3,264
Includes convertibles and preferred stock which is being	treated as debt				
er share (THB)					
Book value per share	6.02	6.46	6.93	7.38	7.88
Tangible book value per share	6.02	6.46	6.93	7.38	7.88
Financial strength					
let debt/equity (%)	(36.1)	(37.3)	(42.3)	(46.5)	(50.5)
let debt/total assets (%)	(30.8)	(32.0)	(36.4)	(40.3)	(43.7)
Current ratio (x)	(30.8)	(32.0) 3.6	(36.4)	(40.1)	(43.7)
F interest cover (x)	(69.7)	(13.2)	(31.5)	(26.9)	(25.2)
aluation	2022	2023	2024E	2025E	20265
ecurring P/E (x) *	24.7	25.1	23.2	21.3	19.4
ecurring P/E @ target price (x) *	30.5	31.0	28.7	26.4	24.0
teported P/E (x)	24.7	25.1	23.2	21.3	19.4
Dividend yield (%)	1.6	1.7	2.2	2.3	2.6
Price/book (x)	3.0	2.8	2.6	2.4	2.3
	2.0	2.8	2.6	2.4	2.3
rice/tangible book (x)	3.0	2.0			
Price/tangible book (x) EV/EBITDA (x) **	3.0 12.4	12.6	11.1	9.9	8.8
				9.9 12.8	8.8 11.5

Sources: Praram 9 Hospital; FSSIA estimates



Praram 9 Hospital PCL (PR9 TB)



54.08 /100

Exhibit 4: FSSIA ESG score implication

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
$\star\star\star\star$	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 5: ESG – peer comparison

	FSSIA			Dome	estic ratings	\$		Global ratings						Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21				4.00	4.00		Medium	64.29	A	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

Exhibit 6: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	-	2.33	2.43
BESG environmental pillar score	_	2.56	2.18
BESG social pillar score	—	1.36	1.52
BESG governance pillar score	_	4.13	4.46
ESG disclosure score	-	37.90	37.90
Environmental disclosure score	_	11.78	11.78
Social disclosure score	_	20.68	20.68
Governance disclosure score	_	81.10	81.10
Environmental			
Emissions reduction initiatives	No	Yes	Yes
Climate change policy	No	Yes	Yes
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	0	0
GHG scope 2 location-based	-	4	6
GHG Scope 3	_	0	5
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	No	Yes	Yes
Total energy consumption	_	7	13
Renewable energy use	—	_	_
Electricity used	_	—	—
Fuel used - natural gas	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 7: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	No	Yes	Yes
Hazardous waste	—	-	_
Total waste	—	_	_
Waste recycled	—	_	_
Waste sent to landfills	—	_	_
Environmental supply chain management	No	No	No
Water policy	No	Yes	Yes
Water consumption		60	151
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	No	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	No	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	_	—	—
Pct disabled in workforce	—	_	
Business ethics policy	No	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes
Health and safety policy	No	Yes	Yes
Lost time incident rate - employees	_	—	_
Total recordable incident rate - employees	_	1	0
Training policy	Yes	Yes	Yes
Fair remuneration policy	No	No	No
Number of employees – CSR	2,083	1,987	2,011
Employee turnover pct	—	11	13
Total hours spent by firm - employee training	14,566	13,462	66,852
Social supply chain management	No	No	No
Governance Board size	10	10	0
	10	10	9
No. of independent directors (ID)	4	7	6
No. of women on board	2 7	2 7	2
No. of non-executive directors on board	Yes		Yes
Company conducts board evaluations	7	Yes 7	
No. of board meetings for the year Board meeting attendance pct	97	100	7 89
	3	3	3
Board duration (years)	No	No	No
Director share ownership guidelines			57
Age of the youngest director	56 72	56 73	57 74
Age of the oldest director	72		5
No. of executives / company managers No. of female executives	2	5 0	5 0
Executive share ownership guidelines Size of audit committee	No 3	No 3	No 3
No. of ID on audit committee	3	3 3	3
	3 4	4	4
Audit committee meetings			
Audit meeting attendance %	100	100 3	100
Size of compensation committee	3	3	3
No. of ID on compensation committee	3	2	3
No. of compensation committee meetings	2	2	2
Compensation meeting attendance %	83	100 3	100
Size of nomination committee	3	3	3
No. of nomination committee meetings	2	2	2
Nomination meeting attendance % Sustainability governance	83	100	100

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating					
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann Only the top- inclusion.	e DJSI World applies a transparent, rules-based component selection cess based on the companies' Total Sustainability Scores resulting n the annual S&P Global Corporate Sustainability Assessment (CSA). Iy the top-ranked companies within each industry are selected for lusion. Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA). ESG Score of less than 45% of the S&P Global ESG Score of the hig scoring company are disqualified. The constituents of the DJSI indices selected from the Eligible Universe.							an S&P Globa of the highest JSI indices are	
Sustainability Investment List (<u>THSI</u>) by The Stock Exchange of Thailand (<u>SET</u>)	managing bu Candidates r 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of th shareholders ome key disq pendent direct related to CG	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of D. during the assessment year. The scoring will be fairly weighted agains nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) mark capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidit; >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI index is a market capitalisation-weighted index, cap 5% quarterly weig maximum, and no cap for number of stocks.							
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD,	th in sustainable develop with support from the Sto ts are from the perspectiv s.	ock Exchange of	Good (80-89), 3 and not rated for equitable treatm	8 for Good (70- or scores below nent of shareh 5%); 4) disclos	ries: 5 for Excell 79), 2 for Fair (6 v 50. Weightings olders (weight 2 sure & transpare	0-69), 1 for P include: 1) th 5% combined)	ass (60-69), e rights; 2) and ; 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of s exercised. The and verifiability	e incorporated and sufficientl e CG compor AGM procect and after the i ufficient informat second assess r; and 3) openne	which shareholders' rights d into business operation y disclosed. All form impu- nents to be evaluated and Jures before the meeting meeting (10%). (The first a tion for voting; and 2) facilita ses 1) the ease of attending n ses for Q&A. The third involve res, resolutions and voting re-	s and information is ortant elements of two nually. The assessment (45%), at the meeting ssesses 1) advance ting how voting rights can be neetings; 2) transparency as the meeting minutes that			four categories: (80-89), and not			
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key contr Certification eciding to becom Intent to kick of acluding risk ass employees, est	Checklist include corrupti rols, and the monitoring a is good for three years. me a CAC certified member s f an 18-month deadline to sul sessment, in place of policy a tablishment of whistleblowing ull stakeholders.)	and developing of tart by submitting a bmit the CAC Checklist for nd control, training of	passed Checkli	st will move fo se members ar	d by a committe r granting certific e twelve highly r chievements.	ation by the C	CAC Council	
<u>Morningstar</u> Sustainalytics	based on an risk is unmar regulatory filing information, co	assessment naged. Source gs, news and ot	isk rating provides an ove of how much of a compai s to be reviewed include corp her media, NGO reports/web sk, ESG controversies, issuer iews.	ny's exposure to ESG porate publications and sites, multi-sector	more risk is unr		score is the sum higher ESG risk i Medium 20-30		d risk. The Severe 40+	
ESG Book	The ESG sco positioned to the principle helps explair over-weightin	ore identifies a outperform c of financial m n future risk-a	sustainable companies th over the long term. The m adteriality including inform djusted performance. Ma ith higher materiality and	ethodology considers nation that significantly teriality is applied by	scores using m	score is calcula ateriality-base	ated as a weight d weights. The s dicating better pe	ed sum of the core is scaled	features	
<u>MSCI</u>				anagement of financially their exposure to ESG ris					ethodology to	
	AAA AA A	8.571-10.00 7.143-8.57(Leader:	leading its industry in m	anaging the most si	gnificant ESG ris	ks and opportunitie	s		
	BBB BB	5.714-7.142 4.286-5.713 2.857-4.28	3 Average:	a mixed or unexception industry peers	al track record of ma	anaging the most	significant ESG ris	ks and opportur	ities relative to	
	B CCC	1.429-2.856 0.000-1.428	Laggard:	lagging its industry base	ed on its high expos	ure and failure to	manage significan	t ESG risks		
Moody's ESG solutions	Moody's ass believes that	a company ii		take into account ESG o to its business model and medium to long term.						
Refinitiv ESG rating	based on pu	blicly availabl	e and auditable data. The	a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performan	ce and insufficier	nt degree of tr		
<u></u>		bal ESG Sco					of ESG risks, opp	oortunities, an	d impacts	
S&P Global		The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100. ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.								
			Bloomberg score evalu score is based on Bloo	ating the company's agg mberg's view of ESG fina	regated Environn Incial materiality.	nental, Social a The score is a	weighted gener	alized mean (power mean)	

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 17.80	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 19-Feb-2024 unless otherwise stated.



RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.